TABLE 1.

Potential prognostic and diagnostic value of ENO1 expression in tumors and cancer-associated anti-ENO1 autoantibodies.

Cancer type	Molecule	Prognostic/diagnostic value	References
Bladder	ENO1	Prognostic	Ji et al., 2019
Breast	ENO1	Prognostic	Tu et al., 2010; Cancemi et al., 2019
Cancer-associated retinopathy	Autoantibodies	Prognostic (progressive blinding)	Adamus et al., 1998
Chronic lymphocytic leukemia	Autoantibodies	Prognostic	Griggio et al., 2017
Colorectal	ENO1	Prognostic	Zhan et al., 2017
Gastric cancer	ENO1	Prognostic	Qian et al., 2017; Qiao et al., 2019; Sun et al., 2019; Xu et al., 2019
Glioma	ENO1	Prognostic	Song et al., 2014
Head and Neck	Both ENO1 and autoantibodies	Prognostic	Tsai et al., 2010; Pranay et al., 2013
Liver	Both ENO1 and autoantibodies	Prognostic/diagnostic	Takashima et al., 2005; Hamaguchi et al., 2008; Zhang et al., 2020
Lung Cancer	Both ENO1 and autoantibodies	Prognostic/Diagnostic	Chang et al., 2006; He et al., 2007; Shih et al., 2010; Hsiao et al., 2015; Dai et al., 2017; Zhang et al., 2018; Zang et al., 2019
Multiple myeloma	ENO1	Prognostic	Ray et al., 2020
Non-Hodgkin’s Lymphoma	ENO1	Prognostic	Zhu et al., 2015
Pancreatic cancer	Both ENO1 and autoantibodies	Prognostic	Tomaino et al., 2011; Sun et al., 2017; Yin et al., 2018; Wang et al., 2019